R&D JP Morgan Week 2025 – Ryan Spencer Join CEO Ryan Spencer of Dynavax Technologies in a video interview discussing JP Morgan Week 2025
Patients JP Morgan Week 2025 – Catherine Owen Adams Explore the insightful video interview with Catherine Owen Adams during JP Morgan Week 2025.
R&D JP Morgan Week 2025 – Paul Hastings At JP Morgan last month, pharmaphorum caught up with Paul Hastings, the CEO of Nkarta, to talk about NK cells and autoimmune diseases.
Digital JP Morgan Week 2025 – Phil Johnson Phil Johnson chat about why he joined Evidation and his excitement about the company’s mission.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.